PMID- 35602773
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 4
DP  - 2022 Apr
TI  - Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor 
      Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia.
PG  - e24284
LID - 10.7759/cureus.24284 [doi]
LID - e24284
AB  - BACKGROUND: Sodium-glucose cotransporter inhibitors are promising medications for 
      improving cardiovascular outcomes in diabetic and non-diabetic patients. The 
      baseline characteristics associated with its prescription in Jazan, Saudi Arabia, 
      are still lacking. OBJECTIVES: This study aims to determine the baseline 
      characteristics associated with its prescription among type 2 diabetic patients 
      in the Jazan region. METHODS: A retrospective cohort study of adult patients with 
      type 2 diabetes mellitus (T2DM) in Jazan region, Saudi Arabia, who received a 
      prescription of sodium-glucose cotransporter 2 inhibitors (SGLT2i) from June 2016 
      to December 2021 was conducted. Categorical baseline characteristics are reported 
      as frequencies, and proportion and continuous variables are reported as means 
      (SD). The crude odds and adjusted ratio (OR) (95% CI) for SGLT2i prescription 
      were then calculated using univariate and multivariate logistic regression 
      analysis. RESULTS: A total of 370 patients who satisfied the inclusion criteria 
      were included in this study. There were 133 patients (36%) who had been 
      prescribed SGLT2i over a median follow-up of five years. Characteristics 
      associated with the prescription were female gender (adjusted odds ratio [aOR]: 
      2.2, 95% Cl: 1.3-3.9), endocrinologist doctors (aOR: 2.4, 95% Cl: 1.3-4.5), 
      patients who had visited the center four times or more (aOR: 10.9, 95% Cl: 
      4.6-25.9), patients who have evidence of DM retinopathy (aOR: 9.7, 95% Cl: 
      2.9-31.7), or patients who are morbidly obese (aOR: 4.1, 95% Cl: 1.1-14.8). 
      CONCLUSION: The sodium-glucose cotransporter inhibitors are under-prescribed 
      among type 2 diabetic patients in the Jazan region despite their availability. 
      Further studies are warranted to address the potential barriers to prescriptions 
      among different medical specialties.
CI  - Copyright (c) 2022, Somaili et al.
FAU - Somaili, Mohammed
AU  - Somaili M
AD  - Internal Medicine, Jazan University, Jazan, SAU.
FAU - Oraibi, Omar
AU  - Oraibi O
AD  - Endocrinology, Jazan University, Jazan, SAU.
FAU - Mohrag, Mostafa
AU  - Mohrag M
AD  - Internal Medicine, Jazan University, Jazan, SAU.
FAU - Hommadi, Abdelrahman
AU  - Hommadi A
AD  - Endocrinology, Ministry of Health Holdings, Jazan, SAU.
FAU - Moafa, Esam
AU  - Moafa E
AD  - Internal Medicine, Jazan University, Jazan, SAU.
FAU - Kulaybi, Abdulrahman
AU  - Kulaybi A
AD  - Medicine and Surgery, Jazan University, Jazan, SAU.
FAU - Shobayli, Sahar
AU  - Shobayli S
AD  - Internal Medicine, Jazan University, Jazan, SAU.
FAU - Moafa, Razan
AU  - Moafa R
AD  - Internal Medicine, Jazan University, Jazan, SAU.
FAU - Mhgfory, Ghadah
AU  - Mhgfory G
AD  - Internal Medicine, Jazan University, Jazan, SAU.
FAU - Jaafari, Afaf
AU  - Jaafari A
AD  - Internal Medicine, Jazan University, Jazan, SAU.
FAU - Shami, Ayman
AU  - Shami A
AD  - Internal Medicine, Jazan University, Jazan, SAU.
FAU - Majrashi, Khalid
AU  - Majrashi K
AD  - Internal Medicine, Jazan University, Jazan, SAU.
LA  - eng
PT  - Journal Article
DEP - 20220419
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9119415
OTO - NOTNLM
OT  - baseline characteristics
OT  - jazan
OT  - saudi arabia
OT  - sodium glucose co-transporter inhibitors
OT  - type 2 diabetes mellitus
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/05/24 06:00
MHDA- 2022/05/24 06:01
PMCR- 2022/04/19
CRDT- 2022/05/23 04:30
PHST- 2022/04/17 00:00 [accepted]
PHST- 2022/05/23 04:30 [entrez]
PHST- 2022/05/24 06:00 [pubmed]
PHST- 2022/05/24 06:01 [medline]
PHST- 2022/04/19 00:00 [pmc-release]
AID - 10.7759/cureus.24284 [doi]
PST - epublish
SO  - Cureus. 2022 Apr 19;14(4):e24284. doi: 10.7759/cureus.24284. eCollection 2022 
      Apr.